Aclarion (NASDAQ:ACON – Get Free Report) and Pheton (NASDAQ:PTHL – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Institutional and Insider Ownership
7.5% of Aclarion shares are held by institutional investors. 0.0% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for Aclarion and Pheton, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
| Pheton | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Aclarion and Pheton”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclarion | $80,000.00 | 86.04 | -$7.23 million | ($7.40) | -0.32 |
| Pheton | $305,215.00 | 5.89 | -$660,000.00 | N/A | N/A |
Pheton has higher revenue and earnings than Aclarion.
Risk and Volatility
Aclarion has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Pheton has a beta of 5.4, meaning that its share price is 440% more volatile than the S&P 500.
Profitability
This table compares Aclarion and Pheton’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclarion | -10,948.81% | -59.34% | -56.12% |
| Pheton | N/A | N/A | N/A |
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
About Pheton
Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
